Largest Phase III trial of novel treatment for hypertension shows promising results

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and effective treatment for people with uncontrolled or resistant hypertension, demonstrating consistent blood pressure reductions across a large and diverse patient population. It is the largest phase three trial of an aldosterone synthase inhibitor for the treatment of hypertension.

Be disciplined, professional, Dr Beyani prods civil servants

CIVIL Service Commission chairperson Choolwe Beyani has called on public officers to be committed to duty and ensure that there is efficiency in the delivery of public services. Dr Beyani says the Commission has recorded significant progress in executing its mandate such as the recruitment of over 4, 000 nurses among the cholera volunteers. He […]

To continue reading, you must subscribe to either DAILY, WEEKLY or MONTHLY Plans.